Intelligence / Healthtech / New Clinical Trials / RemeGen Co., Ltd.
RemeGen Co., Ltd.
13 Nov 2026: Trial registered · RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 13 Nov 2026
- Title
- RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
- Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2, Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07935369
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at RemeGen Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for RemeGen Co., Ltd. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.